In the present study, for the first time, we demonstrated that in CML cells curcumin at sub toxic dose affects the HIF-1α pathway that it is known to promote leukemic cell proliferation and to play a key role in the progressive loss of sensitivity to imatinib [5–7]. Here, HIF1A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.